Etanercept biosimilar - Clover Biopharmaceuticals
Alternative Names: SCB 808Latest Information Update: 13 Jan 2025
At a glance
- Originator Clover Biopharmaceuticals
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Ankylosing spondylitis; Psoriasis; Rheumatoid arthritis